178 related articles for article (PubMed ID: 22546768)
1. Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009.
Utili R; Cogo A; Cristini F; Prisco V; Sagnelli E; Tascini C; Iacoboni C; Capone A; Gattuso G; Angarano G; Petrelli E; Grossi P; Bartezaghi M; Zagni E
J Chemother; 2012 Apr; 24(2):113-21. PubMed ID: 22546768
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.
Gonzalez-Ruiz A; Gargalianos-Kakolyris P; Timerman A; Sarma J; José González Ramallo V; Bouylout K; Trostmann U; Pathan R; Hamed K
Adv Ther; 2015 Jun; 32(6):496-509. PubMed ID: 26108157
[TBL] [Abstract][Full Text] [Related]
5. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.
Seaton RA; Gonzalez-Ruiz A; Cleveland KO; Couch KA; Pathan R; Hamed K
Ann Clin Microbiol Antimicrob; 2016 Mar; 15():18. PubMed ID: 26976128
[TBL] [Abstract][Full Text] [Related]
6. [Daptomycin: pharmacological characteristics and its role in the treatment of gram positive infections].
Araos R; García P; Chanqueo L; Labarca J
Rev Chilena Infectol; 2012 Apr; 29(2):127-31. PubMed ID: 22689024
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
Eisenstein BI; Oleson FB; Baltz RH
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
[TBL] [Abstract][Full Text] [Related]
8. [Daptomycin in diabetic patients].
Montejo M
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():54-8. PubMed ID: 22541977
[TBL] [Abstract][Full Text] [Related]
9. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.
Mohan SS; McDermott BP; Cunha BA
Heart Lung; 2005; 34(1):69-71. PubMed ID: 15647736
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.
Segreti JA; Crank CW; Finney MS
Pharmacotherapy; 2006 Mar; 26(3):347-52. PubMed ID: 16503714
[TBL] [Abstract][Full Text] [Related]
11. Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy.
Falcone M; Russo A; Pompeo ME; Vena A; Marruncheddu L; Ciccaglioni A; Grossi P; Mancini C; Novelli A; Stefani S; Venditti M
Int J Antimicrob Agents; 2012 Jan; 39(1):64-8. PubMed ID: 22047703
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
13. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
Johnson A
Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin in endocarditis and bacteraemia: a British perspective.
Warren RE
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii25-33. PubMed ID: 18829722
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin.
Enoch DA; Bygott JM; Daly ML; Karas JA
J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
[TBL] [Abstract][Full Text] [Related]
16. Daptomycin for the treatment of infective endocarditis: results from a European registry.
Dohmen PM; Guleri A; Capone A; Utili R; Seaton RA; González-Ramallo VJ; Pathan R; Heep M; Chaves RL
J Antimicrob Chemother; 2013 Apr; 68(4):936-42. PubMed ID: 23190763
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacoeconomic analysis of the treatment of methicillin-resistant Staphylococcus aureus with daptomycin or vancomycin].
Rubio-Terrés C; Rubio-Rodríguez D; Majos N; Grau S
Rev Esp Quimioter; 2012 Dec; 25(4):283-92. PubMed ID: 23303261
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Levine DP; Lamp KC
Am J Med; 2007 Oct; 120(10 Suppl 1):S28-33. PubMed ID: 17904948
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.
Falagas ME; Giannopoulou KP; Ntziora F; Vardakas KZ
J Antimicrob Chemother; 2007 Jul; 60(1):7-19. PubMed ID: 17550889
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin in the treatment of bacteremia.
Sakoulas G; Golan Y; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S21-7. PubMed ID: 17904947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
